Amarin Corporation plc argues that an omega-3 supplement marketer should include safety warnings on labels similar to those required for its fish oil-derived drug Vascepa and that the use of “pharma” in the firm’s name is false advertising.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?